Pharmaceutical Product Monograph: Iron Sucrose Injection (20 mg/mL)
In the pharmaceutical industry, Iron Sucrose is a parenteral, colloidal solution of Ferric Hydroxide in complex with Sucrose. As a pharmacist and manufacturer, I view this molecule as a “Nanoparticle Targeted Delivery System”—it is technically designed to mimic the body’s natural iron-storage protein, Ferritin, allowing for the controlled release of elemental iron into the reticuloendothelial system without the high toxicity risks associated with older “Free Iron” preparations.
At your WHO-GMP facility in Mumbai, Iron Sucrose 100 mg/5 mL is a high-demand SKU for Nephrology, Gynecology, and Hematology portfolios. It is the gold standard for rapid iron replenishment when oral iron is either ineffective or poorly tolerated.
Therapeutic Profile: Primary Indications
Iron Sucrose injection is indicated for the treatment of Iron Deficiency Anemia (IDA) in specific clinical settings.
| Indication | Clinical Context | Technical Rationale |
| Chronic Kidney Disease (CKD) | Dialysis / Pre-Dialysis | Gold Standard: Essential for patients on Erythropoietin (EPO) therapy, as the bone marrow needs massive iron “fuel” to create new red blood cells. |
| IBD / GI Disorders | Crohn’s / Celiac | Used when the gut is too inflamed to absorb oral iron tablets or when tablets cause severe gastric distress. |
| Post-Partum Hemorrhage | Maternal Health | Used to rapidly restore hemoglobin levels in women who have lost significant blood during childbirth. |
| Pre-Operative Optimization | Major Surgery | Used to “boost” a patient’s blood count 2–4 weeks before surgery to reduce the need for blood transfusions. |
Mechanism: The Ferritin Mimicry
Iron Sucrose bypasses the complex (and often blocked) intestinal absorption pathway:
Colloidal Stability: The sucrose “shell” prevents the iron from reacting prematurely with proteins in the blood.
Macrophage Uptake: After IV injection, the iron-sucrose complex is taken up by the Macrophages of the liver, spleen, and bone marrow.
Controlled Dissociation: Technically, the iron is released from the sucrose complex over several hours.
Transferrin Binding: The released iron binds to Transferrin, which carries it directly to the bone marrow for Hemoglobin synthesis or to the liver for storage as Ferritin.
The Pharmacist’s “Technical Warning”
The “Test Dose” History: Unlike older Iron Dextran, Iron Sucrose has a very low risk of anaphylaxis. While a formal “test dose” is no longer strictly mandatory by some guidelines, as a pharmacist, I recommend the first 25 mg be infused slowly to monitor for hypersensitivity.
The “No Bolus” Rule: High doses (over 100 mg) must be diluted in 100 mL of 0.9% Normal Saline and infused over at least 15–30 minutes. Rapid bolus can cause Hypotension (low blood pressure) due to transient oxidative stress.
Do Not Mix: Never mix Iron Sucrose with other drugs or nutritional fluids. It is technically stable only in Normal Saline. Mixing with Dextrose can cause the complex to precipitate.
Iron Overload: Treatment must be guided by Serum Ferritin and Transferrin Saturation (TSAT) levels to avoid “Hemosiderosis” (toxic iron buildup in organs).
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
The “Molecular Weight” USP: The efficacy of Iron Sucrose depends on its Molecular Weight Distribution. On your digital marketplace, highlight your Gel Permeation Chromatography (GPC) testing. This ensures your generic is a “highly similar” complex to the innovator (Venofer), preventing the release of toxic “Labile Iron.”
The “Preservative-Free” Advantage: For international B2B tenders (especially in the US, EU, and Middle East), market your Iron Sucrose as Single-Use, Preservative-Free vials. This is a major safety requirement for renal clinics.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Iron Sucrose 100 mg/5 mL to support your registration in international B2B tenders for nephrology and maternal health.